In The News

    • JUL 14 2017

    Musella Foundation Awards Oncoceutics New Research Grant

    The Musella Foundation recently awarded Oncoceutics a $25,000 research grant for a project titled “Clinical Evaluation of DRD5 as a Predictive Biomarker of Response to the selective DRD2 antagonist ONC201.” This will fund Oncoceutics’ work evaluating the impact of dopamine receptor expression on the responsiveness of patient tumors to ONC201, with a focus on glioblastoma

    • JUN 09 2017

    ONC201 Results in Glioblastoma Featured in Bioscience Technology

    The recently published results from a clinical trial of ONC201 in patients with recurrent glioblastoma were featured in a recent article from Bioscience Technology. The full article can be read here.

    • MAY 05 2017

    GPCRs In The News: An Interview with Dr. Michel Bouvier

    Cambridge Healthtech Institute recently spoke with Dr. Michel Bouvier of Université de Montréal about his insights on GPCRs and where the field is headed in coming years. The full interview can be found here.

    • MAY 02 2017

    Patients Needed for New Multiple Myeloma Study – Fox Chase Cancer Center

    The below release about the ongoing Phase I/II clinical study in multiple myeloma was recently distributed by Fox Chase Cancer Center: In addition to the best clinical care available, Fox Chase Cancer Center is home to a team of world-renowned cancer researchers who develop and test therapies not available anywhere else. For more than a